Vicore Pharma Holding AB VICO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Increase in Number of Shares and Votes in Vicore Pharma
-
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
-
Vicore Pharma to Participate in Upcoming Healthcare Conferences
-
Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference
-
Vicore Pharma to Present at the European Respiratory Society Congress 2026
Trading Information
- Previous Close Price
- SEK 8.70
- Day Range
- SEK 9.04–9.64
- 52-Week Range
- SEK 8.56–18.24
- Bid/Ask
- SEK 9.11 / SEK 9.14
- Shares Outstanding
- 281.64M
- Market Cap
- SEK 2.57B
- Volume/Avg
- 1M / 688,135
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 573.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
- Website
- https://www.vicorepharma.com
Valuation
|
Metric
|
VICO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.87 |
Price/Sales | 573.65 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VICO
|
|---|---|
Quick Ratio | 12.68 |
Current Ratio | 12.68 |
Interest Coverage | −43.55 |
Quick Ratio
VICO
Profitability
|
Metric
|
VICO
|
|---|---|
Return on Assets (Normalized) | −49.52% |
Return on Equity (Normalized) | −54.02% |
Return on Invested Capital (Normalized) | −55.88% |
Return on Assets
VICO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|V&mM^z | LOCK|g>^> | $128B | |||
| Moderna Inc
MRNA
| LOCK|GS$%z! | LOCK|p@% | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|J<wH%$< | LOCK|c#xb& | $76B | |||
| argenx SE ADR
ARGX
| LOCK|<f%j?J | LOCK|<c | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k^kWz^# | LOCK|nr | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m!G$wp$ | LOCK|xlCw^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@$#C>GCt | LOCK|Q>G# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@>m^L% | LOCK|?L | $23B | |||
| Incyte Corp
INCY
| LOCK|Z?#ZB&L | LOCK|>! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|pZXc^x | LOCK|Qr | $14B |
United States